12-132626128-AAG-A
Position:
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PVS1
The NM_006231.4(POLE):βc.6518_6519delβ(p.Ser2173PhefsTer130) variant causes a frameshift change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000237 in 1,601,546 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (β β ). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: π 0.000026 ( 0 hom., cov: 33)
Exomes π: 0.000023 ( 0 hom. )
Consequence
POLE
NM_006231.4 frameshift
NM_006231.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 7.77
Genes affected
POLE (HGNC:9177): (DNA polymerase epsilon, catalytic subunit) This gene encodes the catalytic subunit of DNA polymerase epsilon. The enzyme is involved in DNA repair and chromosomal DNA replication. Mutations in this gene have been associated with colorectal cancer 12 and facial dysmorphism, immunodeficiency, livedo, and short stature. [provided by RefSeq, Sep 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
POLE | NM_006231.4 | c.6518_6519del | p.Ser2173PhefsTer130 | frameshift_variant | 46/49 | ENST00000320574.10 | NP_006222.2 | |
POLE | XM_011534795.4 | c.6518_6519del | p.Ser2173PhefsTer56 | frameshift_variant | 46/48 | XP_011533097.1 | ||
POLE | XM_011534797.4 | c.5597_5598del | p.Ser1866PhefsTer56 | frameshift_variant | 38/40 | XP_011533099.1 | ||
POLE | XM_011534802.4 | c.3506_3507del | p.Ser1169PhefsTer56 | frameshift_variant | 22/24 | XP_011533104.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
POLE | ENST00000320574.10 | c.6518_6519del | p.Ser2173PhefsTer130 | frameshift_variant | 46/49 | 1 | NM_006231.4 | ENSP00000322570 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152216Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
4
AN:
152216
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000346 AC: 8AN: 230954Hom.: 0 AF XY: 0.0000480 AC XY: 6AN XY: 124884
GnomAD3 exomes
AF:
AC:
8
AN:
230954
Hom.:
AF XY:
AC XY:
6
AN XY:
124884
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000235 AC: 34AN: 1449330Hom.: 0 AF XY: 0.0000167 AC XY: 12AN XY: 719940
GnomAD4 exome
AF:
AC:
34
AN:
1449330
Hom.:
AF XY:
AC XY:
12
AN XY:
719940
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152216Hom.: 0 Cov.: 33 AF XY: 0.0000403 AC XY: 3AN XY: 74362
GnomAD4 genome
AF:
AC:
4
AN:
152216
Hom.:
Cov.:
33
AF XY:
AC XY:
3
AN XY:
74362
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 10, 2024 | This sequence change results in a frameshift in the POLE gene (p.Ser2173Phefs*130). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 114 amino acid(s) of the POLE protein and extend the protein by 15 additional amino acid residues. This variant is present in population databases (rs774417192, gnomAD 0.009%). This frameshift has been observed in individual(s) with clinical features of FILS syndrome (PMID: 30503519). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 405609). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jul 26, 2018 | This deletion of two nucleotides in POLE is denoted c.6518_6519delCT at the cDNA level and p.Ser2173PhefsX130 (S2173FfsX130) at the protein level. The normal sequence, with the bases that are deleted in braces, is GACT[CT]TCCT. The deletion causes a frameshift which changes a Serine to a Phenylalanine at codon 2173 in exon 46 of the POLE gene, and results in an extension of the protein. The last 114 amino acids are replaced by 129 incorrect amino acids, disrupting a region that contains the Zinc finger domain (Tahirov 2009). Since the clinical significance of this extension is unclear, we consider c.6518_6519delCT to be a variant of uncertain significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | May 30, 2017 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 02, 2022 | Variant summary: POLE c.6518_6519delCT (p.Ser2173PhefsX130) causes a frameshift which is expected to disrupt the last 114 amino acids and result in an extension of the protein. The variant allele was found at a frequency of 3.5e-05 in 230954 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.6518_6519delCT has been reported in the literature in individuals affected with Intrauterine Growth Retardation, Metaphyseal Dysplasia, Adrenal Hypoplasia Congenita, Genital Anomalies, And Immunodeficiency( Logan_2018). This supporting data is currently insufficient to allow any conclusion about variant significance. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Colorectal cancer, susceptibility to, 12 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Nov 10, 2017 | - - |
Hereditary cancer-predisposing syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 22, 2019 | The c.6518_6519delCT variant, located in coding exon 46 of the POLE gene, results from a deletion of two nucleotides at nucleotide positions 6518 to 6519, causing a translational frameshift with a predicted alternate stop codon (p.S2173Ffs*130). This alteration is expected to result in loss of function by premature protein truncation. However, loss of function of POLE has not been clearly established as a mechanism of disease. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at